Feasibility of radical cardiac-sparing, treatment planning strategies for patients with locally advanced, non-small cell lung cancer.


Journal

Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176

Informations de publication

Date de publication:
Dec 2022
Historique:
revised: 20 06 2022
received: 07 02 2022
accepted: 21 08 2022
pubmed: 15 10 2022
medline: 31 12 2022
entrez: 14 10 2022
Statut: ppublish

Résumé

A set of treatment planning strategies were designed and retrospectively implemented for locally advanced, non-small cell lung cancer (NSCLC) patients in order to minimize cardiac dose without compromising target coverage goals. Retrospective analysis was performed for 20 NSCLC patients prescribed to 60-66 Gy that received a mean heart dose (MHD) ≥10 Gy. Three planning approaches were designed and implemented. The first was a multi-isocentric (MI) volume-modulated arc therapy (VMAT) approach (HEART_MI) with one isocenter located within the tumor and the second chosen up to 10 cm away longitudinally. The second was a noncoplanar (NCP) VMAT approach (HEART_NCP) utilizing up to three large couch angles and a standard arc at couch 0. The final planning strategy took a mixed approach (HEART_HYBRID) utilizing the HEART_NCP strategy for two thirds of the treatment combined with a plan utilizing a pair of opposite-opposed gantry angles for the remaining treatments. Investigational plans were compared to original plans using dose-volume histogram metrics such as organ volume receiving greater than x Gy (Vx) or mean dose (Dmean). Although there was a small but statistically significant decrease in internal target volume coverage for HEART_MI plans and, conversely, a statistically significant increase for HEART_NCP plans, all generated plans met physician-prescribed target constraints. For heart dose, there were statistically significant decreases in all heart metrics and particularly MHD for the HEART_MI (9.8 vs. 15.4 Gy [p < 0.001], respectively), HEART_NCP (9.2 vs. 15.4 Gy [p < 0.001]), respectively), and HEART_HYBRID (7.9 vs. 15.4 Gy [p < 0.001], respectively) strategies. The strategy providing the best compromise between plan quality and cardiac dose reduction was HEART_NCP, which produced MHD reductions of 37.6% ± 12.9% (6.2 ± 3.4 Gy) relative to original plans. This strategy could potentially reduce adverse cardiac events, leading to improved quality of life for these patients.

Identifiants

pubmed: 36237114
doi: 10.1002/acm2.13784
pmc: PMC9797161
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13784

Informations de copyright

© 2022 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine.

Références

Semin Radiat Oncol. 2021 Apr;31(2):112-119
pubmed: 33610267
Blood. 2017 Apr 20;129(16):2257-2265
pubmed: 28143884
J Radiat Res. 2020 Mar 23;61(2):298-306
pubmed: 32052040
Radiol Oncol. 2018 Feb 21;52(3):281-288
pubmed: 30210037
J Am Coll Cardiol. 2019 Jun 18;73(23):2976-2987
pubmed: 31196455
J Appl Clin Med Phys. 2022 Dec;23(12):e13784
pubmed: 36237114
Sci Rep. 2019 Oct 30;9(1):15671
pubmed: 31666647
JAMA Oncol. 2016 Mar;2(3):359-67
pubmed: 26606200
Medicine (Baltimore). 2020 Sep 18;99(38):e21964
pubmed: 32957314
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
J Neurosurg. 2000 Dec;93 Suppl 3:219-22
pubmed: 11143252
Ann Oncol. 2017 May 1;28(5):1084-1089
pubmed: 28453703
Phys Med Biol. 2017 Jul 06;62(15):5926-5944
pubmed: 28486217
J Thorac Oncol. 2017 Feb;12(2):293-301
pubmed: 27743888
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):582-589
pubmed: 30630029
Strahlenther Onkol. 2019 Oct;195(10):861-871
pubmed: 31321461
Support Care Cancer. 2016 Aug;24(8):3669-76
pubmed: 27260018
Pract Radiat Oncol. 2015 May-Jun;5(3):141-148
pubmed: 25957184
J Clin Oncol. 2017 Apr 10;35(11):1171-1178
pubmed: 28095159
Pract Radiat Oncol. 2020 May - Jun;10(3):e147-e154
pubmed: 31586483
J Thorac Oncol. 2018 Oct;13(10):1508-1518
pubmed: 29883836
Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):996-1003
pubmed: 34774998
J Clin Oncol. 2017 May 1;35(13):1387-1394
pubmed: 28113017
J Clin Oncol. 2017 May 1;35(13):1395-1402
pubmed: 28301264
J Clin Oncol. 2020 Mar 1;38(7):706-714
pubmed: 31841363
Lung. 2020 Dec;198(6):897-907
pubmed: 33175991
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342

Auteurs

Joshua P Kim (JP)

Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan, USA.

Jake Dewalt (J)

Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan, USA.

Aharon Feldman (A)

Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan, USA.

Khaled Adil (K)

Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan, USA.

Benjamin Movsas (B)

Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan, USA.

Indrin J Chetty (IJ)

Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH